vs
Side-by-side financial comparison of Equity Residential (EQR) and Royalty Pharma plc (RPRX). Click either name above to swap in a different company.
Equity Residential is the larger business by last-quarter revenue ($781.9M vs $622.0M, roughly 1.3× Royalty Pharma plc). Equity Residential runs the higher net margin — 48.9% vs 34.4%, a 14.4% gap on every dollar of revenue. On growth, Royalty Pharma plc posted the faster year-over-year revenue change (4.8% vs 2.0%). Over the past eight quarters, Royalty Pharma plc's revenue compounded faster (4.6% CAGR vs 3.4%).
Equity Residential is a United States–based publicly traded real estate investment trust that invests in apartments.
Acceleron Pharma, Inc. is an American clinical stage biopharmaceutical company based in Cambridge, Massachusetts with a broad focus on developing medicines that regulate the transforming growth factor beta (TGF-β) superfamily of proteins, which play fundamental roles in the growth and repair of cells and tissues such as red blood cells, muscle, bone, and blood vessels.
EQR vs RPRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $781.9M | $622.0M |
| Net Profit | $382.1M | $214.2M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 62.4% |
| Net Margin | 48.9% | 34.4% |
| Revenue YoY | 2.0% | 4.8% |
| Net Profit YoY | -8.8% | 2.9% |
| EPS (diluted) | $1.01 | $0.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $781.9M | $622.0M | ||
| Q3 25 | $782.4M | $609.3M | ||
| Q2 25 | $768.8M | $578.7M | ||
| Q1 25 | $760.8M | $568.2M | ||
| Q4 24 | $766.8M | $593.6M | ||
| Q3 24 | $748.3M | $564.7M | ||
| Q2 24 | $734.2M | $537.3M | ||
| Q1 24 | $730.8M | $568.0M |
| Q4 25 | $382.1M | $214.2M | ||
| Q3 25 | $289.1M | $288.2M | ||
| Q2 25 | $192.4M | $30.2M | ||
| Q1 25 | $256.6M | $238.3M | ||
| Q4 24 | $419.1M | $208.2M | ||
| Q3 24 | $143.4M | $544.0M | ||
| Q2 24 | $177.5M | $102.0M | ||
| Q1 24 | $295.8M | $4.8M |
| Q4 25 | 50.6% | 62.4% | ||
| Q3 25 | 38.5% | 70.1% | ||
| Q2 25 | 26.6% | 36.3% | ||
| Q1 25 | 35.7% | 94.0% | ||
| Q4 24 | 57.2% | 60.9% | ||
| Q3 24 | 20.1% | — | ||
| Q2 24 | 25.3% | 50.2% | ||
| Q1 24 | 42.0% | -13.0% |
| Q4 25 | 48.9% | 34.4% | ||
| Q3 25 | 36.9% | 47.3% | ||
| Q2 25 | 25.0% | 5.2% | ||
| Q1 25 | 33.7% | 41.9% | ||
| Q4 24 | 54.7% | 35.1% | ||
| Q3 24 | 19.2% | 96.3% | ||
| Q2 24 | 24.2% | 19.0% | ||
| Q1 24 | 40.5% | 0.8% |
| Q4 25 | $1.01 | $0.49 | ||
| Q3 25 | $0.76 | $0.67 | ||
| Q2 25 | $0.50 | $0.07 | ||
| Q1 25 | $0.67 | $0.55 | ||
| Q4 24 | $1.10 | $0.46 | ||
| Q3 24 | $0.38 | $1.21 | ||
| Q2 24 | $0.47 | $0.23 | ||
| Q1 24 | $0.77 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $55.9M | $618.7M |
| Total DebtLower is stronger | $8.2B | $9.0B |
| Stockholders' EquityBook value | $11.0B | $9.7B |
| Total Assets | $20.7B | $19.6B |
| Debt / EquityLower = less leverage | 0.75× | 0.92× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $55.9M | $618.7M | ||
| Q3 25 | $93.1M | $938.9M | ||
| Q2 25 | $31.3M | $631.9M | ||
| Q1 25 | $39.8M | $1.1B | ||
| Q4 24 | $62.3M | $929.0M | ||
| Q3 24 | $28.6M | $950.1M | ||
| Q2 24 | $38.3M | $1.8B | ||
| Q1 24 | $44.5M | $843.0M |
| Q4 25 | $8.2B | $9.0B | ||
| Q3 25 | — | $8.9B | ||
| Q2 25 | — | $8.0B | ||
| Q1 25 | — | $7.6B | ||
| Q4 24 | $8.2B | $7.6B | ||
| Q3 24 | — | $7.6B | ||
| Q2 24 | — | $7.6B | ||
| Q1 24 | — | $6.1B |
| Q4 25 | $11.0B | $9.7B | ||
| Q3 25 | $11.1B | $9.6B | ||
| Q2 25 | $11.0B | $9.5B | ||
| Q1 25 | $11.0B | $9.8B | ||
| Q4 24 | $11.0B | $10.3B | ||
| Q3 24 | $10.9B | $10.3B | ||
| Q2 24 | $11.0B | $9.8B | ||
| Q1 24 | $11.1B | $9.9B |
| Q4 25 | $20.7B | $19.6B | ||
| Q3 25 | $21.1B | $19.3B | ||
| Q2 25 | $21.0B | $18.3B | ||
| Q1 25 | $20.6B | $17.6B | ||
| Q4 24 | $20.8B | $18.2B | ||
| Q3 24 | $20.9B | $18.0B | ||
| Q2 24 | $19.8B | $17.7B | ||
| Q1 24 | $19.9B | $16.1B |
| Q4 25 | 0.75× | 0.92× | ||
| Q3 25 | — | 0.93× | ||
| Q2 25 | — | 0.84× | ||
| Q1 25 | — | 0.78× | ||
| Q4 24 | 0.74× | 0.74× | ||
| Q3 24 | — | 0.74× | ||
| Q2 24 | — | 0.78× | ||
| Q1 24 | — | 0.62× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $387.0M | $827.1M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | 1.01× | 3.86× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $387.0M | $827.1M | ||
| Q3 25 | $476.7M | $702.6M | ||
| Q2 25 | $359.5M | $364.0M | ||
| Q1 25 | $425.5M | $596.1M | ||
| Q4 24 | $354.2M | $742.5M | ||
| Q3 24 | $401.4M | $703.6M | ||
| Q2 24 | $396.9M | $658.2M | ||
| Q1 24 | $421.0M | $664.6M |
| Q4 25 | 1.01× | 3.86× | ||
| Q3 25 | 1.65× | 2.44× | ||
| Q2 25 | 1.87× | 12.06× | ||
| Q1 25 | 1.66× | 2.50× | ||
| Q4 24 | 0.85× | 3.57× | ||
| Q3 24 | 2.80× | 1.29× | ||
| Q2 24 | 2.24× | 6.45× | ||
| Q1 24 | 1.42× | 139.10× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
EQR
Segment breakdown not available.
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
